جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

1 مُخرَج نتائج البحث عن «Cell cycle»

تصحيحوصول مفتوح2024

Corrigendum: Targeting p53 misfolding conundrum by stabilizing agents and their analogues in breast cancer therapy: a comprehensive computational analysis

Frontiers in Pharmacology · مجلد 15 · 1494110-1494110

Breast carcinoma is one of the most frequent malignancies diagnosed globally and the chief cause of mortality among females (Siegel et al., 2021;Mir and Qayoom, 2023). Nearly 30% of all cancer incidences in women are due to breast cancer (Sung et al., 2021). Globally, BC represents recurrent malignancy among women. In 2020, it exceeded lung cancer to become the top reason of cancer incidence worldwide. A total of 2.3 million additional cases were anticipated, accounting for approximately 11.7% of all cancer cases (Hall et al., 1990).Epidemiological studies have revealed that the burden of breast cancer globally is thought to cross nearly 2 million by the year 2030 (Wooster et al., 1994). The primary major gene that was identified to be associated with hereditary BC in 1990 is BRCA1. Additionally, it was identified by employing linkage analysis in families by exploring suggestive pedigrees (Gallanis et al., 2021). Following this, BRCA2 was mapped to chromosome 13 in 1994 (Baldin et al., 1993). An alteration in either BRCA1 or BRCA2 increases susceptibility to cancer risk, especially BC. Metastatic breast cancer remains almost completely incurable, with an average overall survival (OS) of 3 years and a merely 25% 5-year OS (Cardoso et al., 2018;Sofi et al., 2022a).Although there have been significant advances in the strategies for curing breast cancer, the poor prognosis is still a matter of concern (Waks and Winer, 2019;Sofi et al., 2022b;Mir and Haq, 2023a;Qayoom et al., 2023a;Mir and Haq, 2023b). Due to its heterogeneous nature, it becomes hard to access the surviving individuals (Turashvili and Brogi, 2017;Mehraj et al., 2021;Qayoom et al., 2021). Multiple studies on breast cancer previously identified several genes which possess prognostic value. However, the developing field of bioinformatics along with advancing algorithms has provided researchers with the environment to discover potential genes by employing a different approach (Mehraj et al., 2022;Qayoom et al., 2023b;Sofi et al., 2023). The p53 protein has an essential role in prevention of genomic mutation in the body, but this protein is prone to mutations at a higher rate as witnessed in cancers. Moreover, a malfunction is witnessed in approximately all cancers along the p53 pathway. The altered p53 protein not only loses its function but is also susceptible to misfolding and accumulation, ultimately leading to the formation of amyloid aggregates. Protein misfolding and accumulation have a part to play in cancer development. Recognized as the "guardian of the genome," p53 plays a crucial role in preventing genomic mutations. Structurally, p53 represents a tetrameric transcription factor that modulates multiple cellular roles like expression of target genes that lead to apoptosis, repair of DNA, and arrest of the cell cycle in damaged cells in addition to cellular metabolism (Helton and Chen, 2007;Lukin et al., 2015;Mir et al., 2023a). Due to the fact that more than 50% of cancers are caused due to direct point mutations of p53 (Petitjean et al., 2007;Olivier et al., 2010) and the p53 malfunction as seen in aggressive cancer types like gastric cancer (Blanchet et al., 2021); thus, reverting or restoring the normal p53 function is a marked strategy for possible cancer cure (Hong et al., 2014;Bykov et al., 2018;Miller et al., 2020). The levels of P53 are highly modulated through posttranslational alterations and a pivotal modifier modulator mouse double minute 2 homolog (MDM2). However, during cellular stress, there is an inhibition to p53 degradation; in addition, the protein is accumulated in the nucleus (Friedman et al., 1993;Nag et al., 2013;Mir et al., 2022). The same causes target gene upregulation and triggers reaction mechanisms to bypass the multiplication of injured cells (Brooks and Gu, 2010). For example, when DNA damage occurs, p53 may either force the injured cell to be removed or trigger a cell cycle blockage mechanism that allows DNA repair to proceed (Helton and Chen, 2007;Lukin et al., 2015). The studies have revealed that the DNA-binding domain (DBD) of wild-type p53 displays less thermodynamic and kinetic stability (Natan et al., 2011) and several mutations lead to instability, ultimately causing protein unfolding. Cancer cells acquire high amounts of mutant p53 because it avoids the MDM2-mediated proteasomal destruction (Scian et al., 2004).MDM2 has been shown to play a post-ubiquitination function in the degradation of p53 (Kulikov et al., 2010). Aggregation and unfolding are intricate processes; however, destabilization exposes an adhesive sequence that attaches to the same section in other p53 units and triggers aggregation. Consequently, there is significant interest in the creation of novel agents that can both stabilize folded structures and prevent aggregation or split preformed aggregates (Miller et al., 2020;Miller et al., 2022). There are multiple ways through which altered p53 protein can be stabilized in its active and folded form. A comprehensive set of Michael acceptors, including CP-31398 and PRIMA1, has been seen to rectify the native information on mutant p53 and initiate p53-dependent cytotoxicity (Foster et al., 1999;Bykov et al., 2002;Rangel et al., 2019;Mir et al., 2023b). PhiKan-083 represents a small molecule and a carbazole derivative, which binds to the surface cavity and leads to the stabilization of a p53 mutant, namely, Y220C, possessing a Kd of 167 μM. Thus, we attempted to explore PhiKan-083 for breast cancer research. Y220C mutation, which is not involved in DNA interaction, causes a destabilization of the protein. PhiKan-083 binding stabilizes the mutant p53 and slows the rate of denaturation.Hence, for this study, we screened and examined many analogs of PhiKan-083 with better docking scores in comparison to PhiKan-083 for stabilizing misfolded p53. We evaluated the molecule-to-molecule docking of selected compounds to determine the therapeutic potential of screened PhiKan-083-related analogs by calculating the drug-likeliness of those compounds. This work identified two novel compounds that, in addition to their potential as PhiKan-083 substitutes, have advantages such as potential activity against a variety of p53-misfolded malignancies and not just breast cancer. We also looked at p53's expression patterns and predictive values across a range of cancer types, especially breast cancer.UALCAN (http://ualcan.path.uab.edu/) represents a web-based interactive portal to investigate cancer omics data (Chandrashekar et al., 2017). UALCAN has been made to furnish access to publicly available cancer OMICS data easily with the aim of running in silico validation of genes that are of interest or to identify related biomarkers. These databases furnish the graphical representation along with the plots displaying the expression profiles along with the subject survival information. We selected TCGA invasive breast carcinoma data, and P53 expression was examined among different cancer stages, sample types, and sub-classes.TIMER 2.0 (http://timer.comp-genomics.org/) is an instructive tool used to thoroughly evaluate the expression and quantification of immune infiltrates across malignancies. Users can investigate the connection between gene expression and other variables using the database's algorithms, including quanTIseq, CIBERSORT, MCPcounter, and EPIC algorithms; the status of its mutation; and its association with different immune cell kinds. To better comprehend the gene expression profiles of all malignancies, a heatmap of TP53 was created using TIMER 2.0 (Li et al., 2020).Through TCGA and GTEx projects, RNA-sequencing expression data from 9,736 tumors and 8,587 normal samples were analyzed using the web-based application GEPIA2 (http://gepia2.cancer-pku.cn). Subject survival analysis, dimensionality reduction study, identification of related genes, profiling based on cancer types or pathological stages, assessment of differential expression between tumors and normal tissues, and correlation analysis are a few of the resources that can be tailored. By gathering RNA-seq datasets from the UCSC Xena project (http://xena.ucsc.edu), the GEPIA2 followed a pre-established process (Tang et al., 2019). The TP53 expression in varied cancers was obtained by employing the GEPIA2 portal.The breast cancer gene-expressionminer v4.5 (http://bcgenex.ico.unicancer.fr/) is a bioinformatics tool available online that contains published BC transcriptomic and RNA-seq data in an annotated form (Jézéquel et al., 2012;Jezequel et al., 2013). It was employed to analyze the link between p53 expression levels and distinct clinical factors of breast tumor subjects. P53 expression analysis results were analyzed for basal-like luminal A and luminal B types.For researchers who want to carefully examine the functional proteomics of various cancer types, the University of Texas MD Anderson Cancer Center's Cancer Proteome Atlas Portal is a goto source (https://tcpaportal.org/tcpa/). Using the website's database of patient cohorts, the users can search through the datasets of patient tumors that have been obtained and sequenced by the Center. Users can obtain thorough explanations of each dataset and use a network model or heatmap to evaluate the interactions of the proteins in the data. This website offers a database of cancer cell lines in addition to the patient's cohort database, which researchers can browse and analyze.The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), both of which are divisions of the National Institutes of Health of the U.S. Department of Health and Human Services, have collaborated on it (https://portal.gdc.cancer.gov/). A pilot study for the Cancer Genome Atlas was conducted to see whether a larger project must be undertaken to systematically examine every type of genetic mutation connected to human cancer. Next, using matched normal samples, the scientists molecularly defined almost 20,000 initial cancer samples from 33 distinct cancer types. It is open to all members of the scientific community to use the almost 2.5 petabytes of data generated by TCGA.Since 1992, PredictProtein (https://predictprotein.org) has predicted the structure and functional characteristics of proteins using sequence analysis. Multiple sequence alignments anticipated structural elements [solvent accessibility, secondary structure, coiled-coil regions, transmembrane helices (TMSEG) and strands, disulfide bonds, and disordered areas] and functional elements are returned in response to a protein sequence query. Among the analysis techniques included in the service are functional region identification (ConSurf), homologybased inference of GO terms (meta-student), precise subcellular localization prediction (LocTree3), protein-polynucleotide binding sites (SomeNA), protein-polynucleotide binding sites (ISIS2), and predictions of the impact of point mutations (non-synonymous SNPs) on protein function (SNAP2). Their objective has consistently been to provide a tailored solution that satisfies the needs of researchers with less experience in bioinformatics. To achieve this, the PredictProtein results are given as text along with a number of coherent, engaging, and visually appealing images. The sources and web server may be accessed at (http://ppopen.rostlab.org).In this work, PhiKan-083 served as the reference compound, and 100 compounds with similar structural properties were examined. We collected these compounds from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and investigated all of the physico-chemical characteristics of the compounds. The specific compounds were analyzed using Discovery Studio v18 after copying them in SDF format (Kim et al., 2019).The retrieved PhiKan-083 analogues were assessed for drug-likeness using Swiss ADME, an online portal that assesses a drug's potential by examining characteristics such as Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) of the selected 100 analogues (http://www.swissadme.ch). Numerous parameters, such as hydrogen bond acceptors (nHBAs), the log of the n-octanol/water partition coefficient (LogP), hydrogen bond donors (nHBDs), molecular polar surface area (PSA), molecular weight (MW), and number of rotatable bonds (nRotBs), were calculated by incorporating Lipinski's rule of five and the Veber rule. The ADMET prediction technique took into account a number of parameters, including aqueous solubility, cytochrome P450 (CYP) 2D6 inhibition, hepatotoxicity, intestinal absorption, and plasma protein binding. After being chosen, the compounds that complied with ADMET drug likeliness guidelines underwent molecular docking (Rudrapal et al., 2022).The target protein TP53 (PDB ID 8dc4) was obtained from the Protein Data Bank (PDB) in a PDB format (Kulikov et al., 2010). By removing the extra structural moieties like heteroatoms, water molecules, and any associated ligands, the p53 protein was cleared up for further study using the Discovery studio (Nguyen et al., 2014).To ascertain the ligands' affinities for binding to TP53, the compounds were first exposed to molecular docking after undergoing ADMET analysis. Every ligand was docked with the TP53 protein using Auto Dock v4.2.6. Using the co-crystallized X-ray structure of the p53 protein from the RCSB PDB, the binding cavity was built. The co-crystallized ligand's three spacers' residue locations were computed. Following the selection of a cavity, the energy was reduced by applying conjugate gradient and steepest descent algorithms. By merging the nonpolar hydrogens, the receptor and target molecules were finally stored in pdbqt format. We created grid boxes at 0.3 intervals. The protein-ligand complex was docked using the Lamarckian Genetic Algorithm (LGA) in order to determine the lowest free energy of binding (G). Three similar sets of molecular modeling experiments were carried out, with the default settings being a maximum of 2700 generations, 2,500,000 evaluations, and 50 solutions each set (Qayoom et al., 2022).As shown in the heatmap in Figure 1 A, the TIMER 2.0 analysis of the TP53 expression pattern showed overexpression of TP53 across all TCGA datasets. TP53 levels were further assessed using CPTAC samples from the UALCAN database. When compared to normal samples, it was also discovered that the levels of the protein TP53 were significantly raised in a number Using the web-based Enrichr programme for GO analysis, it was demonstrated that MF was considerably enriched compared to BP and CC. The Figure 3 Using KM-plotter from GEPIA2, the prognostic significance of TP53 was assessed across all cancer types. The relationship between overall survival (OS) and relapse-free survival (RFS) and the median expression of TP53 was investigated. According to the study, reduced overall survival (OS) is associated with elevated TP53 expression in the ACC, BRCA, KIRP, LAML,LGG, LIHC, PRAD, SARC, THCA, and UCS Figure 4. The hazard ratio for all malignancies ranged from 1 to 12, with LIHC having the lowest and PRAD having the highest. High TP53 mRNA levels are linked to worse relapse-free survival (RFS) in LGG, UCS, and BRCA, followed by LAML, SARC, ACC, KIRP, LIHC, PRAD, and THCA according to the connection between TP53 mRNA levels and RFS. These investigations demonstrated the importance of TP53 in cancer prognosis, making it a promising target for treating various malignancies. Using UALCAN database, we analyzed the expression pattern of p53 in breast cancer. The heat map was generated by correlating p53 with other overexpressed genes in BC using correlation coefficient The study showed that among all the genes, p53 was We compared the p53 expression in both normal and tumor samples, p53 was in breast cancer. Using the same database, we also analyzed the expression of p53 among various of BC the major associated with p53 misfolding is due to its point mutation we the sequence of P53 using database to the of the status of It was revealed that p53 protein sequence has higher of structural mutations that have significantly its its tumor protein misfolding is it was further assessed to the of mutations that are or mutations that lead to of tumor It was seen that protein misfolding to the of function potential of P53 protein as is shown in the Figure was revealed from the results that P53 protein expression was highly in several cancers including breast cancer and the misfolding was to its of function tumor development. We further the protein secondary structure using the tool and the functional of point mutations of p53 protein and the of it by a heatmap using as shown in Figure for its potential and higher of cases due to the same In order to 100 molecules that are similar to the PubChem database was Following that, the compounds were examined ADMET analysis. compounds specific drug-likeliness characteristics were from the screened including PhiKan-083 as in Using molecular docking the binding of these compounds with TP53 was further Following ADMET each drug underwent a molecular docking study with the target TP53 activity of the was from the binding of the compounds. According to the study, two with the PubChem and higher binding compared to the reference molecule The TIMER 2.0 analysis of the TP53 expression pattern revealed overexpression of TP53 across all TCGA datasets. TP53 levels were further assessed using CPTAC samples from the UALCAN database. After with normal samples, it was also witnessed that the levels of TP53 protein were significantly elevated in various tumor GEPIA2 database, we further examined the expression pattern of TP53 in several malignancies. These results that TP53 is highly in several malignancies, including BRCA, luminal A, luminal and the it was witnessed that MF was significantly enriched in comparison to BP and through GO analysis. By employing KM-plotter from GEPIA2, the prognostic importance of TP53 was assessed across all cancer types. the study, reduced overall survival (OS) was linked with TP53 expression in the ACC, BRCA, KIRP, LAML, LGG, LIHC, PRAD, SARC, THCA, and TP53 mRNA levels were to worse relapse-free survival (RFS) in LGG, UCS, and BRCA, followed by LAML, SARC, ACC, KIRP, LIHC, PRAD, and THCA as the link between TP53 mRNA levels and RFS. These investigations demonstrated the significance of TP53 in cancer prognosis, it as a promising target for treating various malignancies. UALCAN database, we analyzed the expression pattern of p53 in breast cancer. is the most aggressive of breast cancer, study revealed that among all P53 was in and it was most in the major associated with p53 misfolding is due to its point mutation we examined the sequence of P53 using database to the of the status of It was that protein misfolding to the of function potential of P53 protein. We further the protein secondary structure by exploring the web-based PredictProtein tool and examined the functional of point mutations of p53 protein and its by a heatmap using In order to analyze the 100 molecules that are similar to the PubChem database was Following this, the same compounds were analyzed through ADMET analysis. The top compounds specific drug-likeliness characteristics were from the screened including PhiKan-083 by using the molecular docking the binding of these compounds with TP53 was the we to explore the expression of TP53 in its therapeutic prognostic and the impact of overexpression on overall and relapse-free survival in a range of cancers. We the TP53 expression profiles across all TCGA using the TIMER 2.0 database. When TP53 was compared to normal samples for study of differential it was shown that malignancies such BRCA, and elevated TP53 According to this study, TP53 is a major in a number of making it a TP53 overexpression was shown to be caused by gene alteration and TCGA analysis was used to evaluate this examining the correlation between mRNA expression and survival demonstrated a significant association with many malignancies with elevated hazard study a correlation between high TP53 mRNA levels and poor OS in ACC, BRCA, KIRP, LAML, LGG, LIHC, PRAD, SARC, THCA, and free survival (RFS) has been associated with higher TP53 mRNA levels in KIRP, LIHC, and we the impact of point mutations on p53 protein misfolding using database. The of genetic alteration a role in of of P53 protein. we examined the potential role of a P53 stabilizing and its analogues in breast cancer. We screened 100 analogues to PhiKan-083 and examined them for their drug-likeliness Among those compounds were selected for their drug-likeliness and further investigated molecular docking We two novel compounds and analogues to PhiKan-083 that may be further for their therapeutic potential by P53 misfolding not only for breast cancer but for other as

breast cancerBRCA1BRCA2metastatic breast cancer